Autonomix Medical, Inc. (NASDAQ: AMIX) to Participate in the Virtual Investor Closing Bell Series
Rhea-AI Summary
Autonomix Medical (NASDAQ: AMIX), a medical device company specializing in nervous system disease diagnosis and treatment technologies, has announced its participation in the Virtual Investor Closing Bell Series scheduled for Wednesday, January 22, 2025, at 4:00 PM ET.
During the event, CEO Brad Hauser will deliver a corporate overview and business outlook. The format includes a moderated discussion with a live Q&A session where investors can submit questions. The company will address as many queries as time permits.
The presentation will be accessible through a live video webcast on the Events page in the Investors section of autonomix.com. A replay will be available two hours after the live event and remain accessible for 90 days.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, AMIX gained 10.55%, reflecting a significant positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Live video webcast on Wednesday, January 22nd at 4:00 PM ET
THE WOODLANDS, TX, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that it will participate in the Virtual Investor Closing Bell Series on Wednesday, January 22, 2025 at 4:00 PM ET.
As part of the event, Brad Hauser, Chief Executive Officer of Autonomix, will provide a corporate overview and business outlook. In addition to the moderated discussion, investors and interested parties will have the opportunity to submit questions live during the event. The Company will answer as many questions as possible in the time allowed.
A live video webcast will be available on the Events page under the Investors section of the Company’s website (autonomix.com). A webcast replay will be available two hours following the live event and will be accessible for 90 days.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with approximately 3,000 times greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Investor and Media Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
autonomix@jtcir.com
FAQ
When is Autonomix Medical (AMIX) participating in the Virtual Investor Closing Bell Series?
How can investors watch the AMIX Virtual Investor Closing Bell presentation?
How long will the AMIX Virtual Investor Closing Bell replay be available?
Will there be a Q&A session during the AMIX Virtual Investor presentation?
What topics will be covered in the AMIX Virtual Investor presentation?
